SOURCE: ONE Bio, Corp.

February 02, 2011 08:00 ET

ONE Bio Signs U.S. Distribution Agreement

Agreement Plays Important Role in Company's U.S. Expansion Strategy

MIAMI, FL--(Marketwire - February 2, 2011) - ONE Bio, Corp. ("ONE" or the "Company") (OTCBB: ONBI), an innovative company utilizing green process manufacturing to produce raw chemicals and herbal extracts, natural and health supplements and organic products, announced today that its subsidiary, Green Planet Bioengineering Co., Ltd., has signed a U.S. distribution agreement with P&G Ingredient, LLC ("P&G"), a producer and distributor of botanical and chemical extracts.

The agreement includes pre-orders for the Company's raw extracts, including resveratrol, stevia leaf powder, 5-HTP, polygonum extract and spirulina powder. Headquartered in New Jersey and operating for over a decade, P&G is a producer in the botanical and chemical extracts field, with product distribution that ranges from raw botanicals and chemical ingredients to API (Active Pharmaceutical Ingredients) and ANI (Active Natural Ingredients).

"This agreement is an important part of our strategy to expand distribution of our highly sought-after raw chemicals and herbal extracts in the United States," stated ONE's CEO, Marius Silvasan. "Our sales strategy for 2011 is focused on expanding our distribution in three key markets: the U.S., China and Japan. The New Jersey/New York region is a strategic entry point in the U.S., as it has the largest concentration of botanical extract and ingredient distributors in the nation. New Jersey is also home to five foreign-trade zones that allow companies involved in international trade to cut, delay or eliminate customs charges, which will increase the competitiveness of our products."

Mr. Silvasan continued, "We have achieved much success in China and Japan and are well positioned for aggressive U.S. expansion this year. In our aging society, a growing number of American consumers are seeking to maintain a healthy lifestyle focused on alternative medicines and preventative care. These key factors will continue to drive increased sales of nutraceutical and health-related products, including organic food products."

"For the first nine months of 2010 25% of our revenue was derived outside of China," continued Mr. Silvasan. "We expect sales outside of China to account for a greater percentage of our total revenue in 2011 as we expand our business in the U.S."

About ONE Bio, Corp.
ONE Bio, Corp. ("ONE") (OTCBB: ONBI) (, headquartered in Miami, FL, with manufacturing facilities in China, is an innovative company utilizing patented green process manufacturing to produce raw chemicals and herbal extracts, natural supplements and organic products. ONE is focused on the Asia Pacific region and the Unites States. Key products include widely recognized Solanesol, CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic bamboo health food and beverages. ONE has experienced solid organic growth driven by a robust demand for its products in China, Japan and the United States.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contact Information